1. Home
  2. LBRDK vs UTHR Comparison

LBRDK vs UTHR Comparison

Compare LBRDK & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty Broadband Corporation Class C

LBRDK

Liberty Broadband Corporation Class C

HOLD

Current Price

$47.64

Market Cap

6.7B

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$488.92

Market Cap

20.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LBRDK
UTHR
Founded
2014
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.7B
20.3B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
LBRDK
UTHR
Price
$47.64
$488.92
Analyst Decision
Buy
Analyst Count
0
12
Target Price
N/A
$495.08
AVG Volume (30 Days)
1.2M
424.3K
Earning Date
11-05-2025
10-29-2025
Dividend Yield
N/A
N/A
EPS Growth
1.38
16.08
EPS
5.51
26.38
Revenue
$1,016,000,000.00
$3,128,400,000.00
Revenue This Year
$8.37
$13.64
Revenue Next Year
$2.91
$5.78
P/E Ratio
$5.70
$18.55
Revenue Growth
306.40
13.50
52 Week Low
$44.63
$266.98
52 Week High
$104.00
$492.62

Technical Indicators

Market Signals
Indicator
LBRDK
UTHR
Relative Strength Index (RSI) 43.00 68.10
Support Level $44.88 $470.13
Resistance Level $46.77 $492.62
Average True Range (ATR) 1.42 10.72
MACD 0.54 -0.53
Stochastic Oscillator 82.05 89.55

Price Performance

Historical Comparison
LBRDK
UTHR

About LBRDK Liberty Broadband Corporation Class C

Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: